BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW

BALA CYNWYD, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

RAPT Therapeutics, Inc. (Nasdaq – RAPT)

Under the terms of the Merger Agreement, RAPT Therapeutics will be acquired by GlaxoSmithKline LLC for $58.00 a share, an estimated aggregate equity value of $2.2 billion. The investigation concerns whether the RAPT Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/rapt-therapeutics-inc-nasdaq-rapt/.

Calavo Growers, Inc. (Nasdaq – CVGW)

Under the terms of the Merger Agreement, Calavo will be acquired by Mission Produce, Inc. (“Mission”) (Nasdaq - AVO) whereby Calavo stockholders will receive $27.00 per share comprised of $14.85 in cash and 0.9790 shares of Mission for each share of Calavo. The transaction values Calavo at a total enterprise value of approximately $430 million. Upon close, Mission shareholders are expected to own approximately 80.3% of the combined company and Calavo shareholders are expected to own approximately 19.7%. The investigation concerns whether the Calavo Growers Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/calavo-growers-inc-nasdaq-cvgw/.

Penumbra, Inc. (NYSE – PEN)

Under the terms of the Merger Agreement, Penumbra will be acquired by Boston Scientific Corporation (NYSE: BSX) in a cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion. The investigation concerns whether the Penumbra Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/penumbra-inc-nyse-pen/.

FONAR Corporation (Nasdaq - FONR)

Under the terms of the Merger Agreement, FONR will be acquired by FONAR, LLC and FONAR Acquisition Sub, Inc. (collectively, “Buyer”) for $19.00 per share of common stock, in an all-cash transaction. The investigation concerns whether the FONAR Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/fonar-corporation-nasdaq-fonr/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

You May Also Be Interested In

• Timbers Captiva Club & Residences Opens Reservations at South Seas, Introducing Captiva’s First New Residential Offering in More Than 30 Years
• Archrock Appoints Mohit Singh Senior Vice President and Chief Financial Officer
• As Global Nickel & Cobalt Demand Accelerates, Awaruite Showing Potential to Become a Strategic Source of Supply